Aarti Pharma

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE0LRU01027
  • NSEID: AARTIPHARM
  • BSEID: 543748
INR
645.75
7.75 (1.21%)
BSENSE

Apr 02

BSE+NSE Vol: 1.85 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Shilpa Medicare
Innova Captab
Akums Drugs
Supriya Lifesci.
Marksans Pharma
Blue Jet Health
Aarti Pharma
FDC
Zota Health Care
SPARC
Sudeep Pharma
Why is Aarti Pharmalabs Ltd ?
1
Poor long term growth as Net Sales has grown by an annual rate of 1.37% and Operating profit at 13.65% over the last 5 years
2
With a fall in Net Sales of -14%, the company declared Very Negative results in Sep 25
  • The company has declared negative results for the last 2 consecutive quarters
  • PBT LESS OI(Q) At Rs 38.64 cr has Fallen at -54.9% (vs previous 4Q average)
  • PAT(Q) At Rs 27.92 cr has Fallen at -58.1% (vs previous 4Q average)
  • ROCE(HY) Lowest at 13.06%
3
Reducing Promoter Confidence
  • Promoters have decreased their stake in the company by -0.84% over the previous quarter and currently hold 42.88% of the company
  • Promoters decreasing their stake may signify reduced confidence in the future of the business
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Aarti Pharma for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Aarti Pharma
-14.39%
0.22
45.63%
Sensex
-4.3%
0.44
11.83%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
-2.13%
EBIT Growth (5y)
4.80%
EBIT to Interest (avg)
12.99
Debt to EBITDA (avg)
0.89
Net Debt to Equity (avg)
0.29
Sales to Capital Employed (avg)
0.91
Tax Ratio
24.11%
Dividend Payout Ratio
16.64%
Pledged Shares
0.01%
Institutional Holding
15.36%
ROCE (avg)
15.33%
ROE (avg)
12.00%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
27
Industry P/E
31
Price to Book Value
2.86
EV to EBIT
20.25
EV to EBITDA
15.45
EV to Capital Employed
2.44
EV to Sales
3.59
PEG Ratio
NA
Dividend Yield
0.62%
ROCE (Latest)
13.24%
ROE (Latest)
11.72%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

0What is working for the Company
Icon
NO KEY POSITIVE TRIGGERS
-22What is not working for the Company
ROCE(HY)

Lowest at 13.06%

PBT LESS OI(Q)

At Rs 66.03 cr has Fallen at -16.0% (vs previous 4Q average

PAT(Q)

At Rs 50.09 cr has Fallen at -16.4% (vs previous 4Q average

DEBT-EQUITY RATIO(HY)

Highest at 0.32 times

NET SALES(Q)

At Rs 432.27 cr has Fallen at -9.3% (vs previous 4Q average

INTEREST(Q)

Highest at Rs 12.58 cr

Loading Valuation Snapshot...
Here's what is not working for Aarti Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 66.03 cr has Fallen at -16.0% (vs previous 4Q average)
over average PBT of the previous four quarters of Rs 78.58 Cr
MOJO Watch
Near term PBT trend is very negative

PBT less Other Income (Rs Cr)

Profit After Tax (PAT) - Quarterly
At Rs 50.09 cr has Fallen at -16.4% (vs previous 4Q average)
over average PAT of the previous four quarters of Rs 59.94 Cr
MOJO Watch
Near term PAT trend is very negative

PAT (Rs Cr)

Net Sales - Quarterly
At Rs 432.27 cr has Fallen at -9.3% (vs previous 4Q average)
over average Net Sales of the previous four quarters of Rs 476.52 Cr
MOJO Watch
Near term sales trend is negative

Net Sales (Rs Cr)

Interest - Quarterly
Highest at Rs 12.58 cr
in the last five quarters and Increased by 17.90 % (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (Rs cr)

Debt-Equity Ratio - Half Yearly
Highest at 0.32 times
in the last five half yearly periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio